Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Fugui Zhang 1, 2 , Yong Li 1 , Hongmei Zhang 1, 2 , Enyi Huang 1, 2 , Lina Gao 1 , Wenping Luo 1, 2 , Qiang Wei 2, 3 , Jiaming Fan 2, 3 , Dongzhe Song 2, 4 , Junyi Liao 2, 3 , Yulong Zou 2, 3 , Feng Liu 2, 3 , Jianxiang Liu 2, 5 , Jiayi Huang 2, 3 , Dan Guo 2, 3 , Chao Ma 2, 6 , Xue Hu 2, 3 , Li Li 2, 7 , Xiangyang Qu 2, 3 , Liqun Chen 2, 3 , Xinyi Yu 2, 3 , Zhicai Zhang 2, 5 , Tingting Wu 2, 8 , Hue H. Luu 2 , Rex C. Haydon 2 , Jinlin Song 1 , Tong-Chuan He 1, 2, 3 , Ping Ji 1 1 Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, and the Affiliated Hospital of Stomatology of Chongqing Medical University, Chongqing, China 2 Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, USA 3 Ministry of Education Key Laboratory of Diagnostic Medicine, and the Affiliated Hospitals of Chongqing Medical University, Chongqing, China 4 Department of Conservative Dentistry and Endodontics, West China Hospital and West China School of Stomatology, Sichuan University, Chengdu, China 5 Department of Orthopaedic Surgery, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 6 Department of General Surgery, The Affiliated Zhongnan Hospital of Wuhan University, Wuhan, China 7 Department of Biomedical Engineering, School of Bioengineering, Chongqing University, Chongqing, China 8 Department of Neurosurgery, The Affiliated Zhongnan Hospital of Wuhan University, Wuhan, China Correspondence to: Tong-Chuan He, email: tche@uchicago.edu Ping Ji, email: jiping-62@hotmail.com Keywords: head and neck squamous cell carcinoma, mebendazole, drug repurposing, keratinization, differentiation therapy Received: October 17, 2016 Accepted: January 09, 2017 Published: January 16, 2017 ABSTRACT Head and neck squamous cell carcinoma (HNSCC) is one of the most common and aggressive types of human cancers worldwide. Nearly a half of HNSCC patients experience recurrence within five years of treatment and develop resistance to chemotherapy. Thus, there is an urgent clinical need to develop safe and novel anticancer therapies for HNSCC. Here, we investigate the possibility of repurposing the anthelmintic drug mebendazole (MBZ) as an anti-HNSCC agent. Using the two commonly-used human HNSCC lines CAL27 and SCC15, we demonstrate MBZ exerts more potent anti-proliferation activity than cisplatin in human HNSCC cells. MBZ effectively inhibits cell proliferation, cell cycle progression and cell migration, and induces apoptosis of HNSCC cells. Mechanistically, MBZ can modulate the cancer-associated pathways including ELK1/SRF, AP1, STAT1/2, MYC/MAX, although the regulatory outcomes are context-dependent. MBZ also synergizes with cisplatin in suppressing cell proliferation and inducing apoptosis of human HNSCC cells. Furthermore, MBZ is shown to promote the terminal differentiation of CAL27 cells and keratinization of CAL27-derived xenograft tumors. Our results are the first to demonstrate that MBZ may exert its anticancer activity by inhibiting proliferation while promoting differentiation of certain HNSCC cancer cells. It’s conceivable the anthelmintic drug MBZ can be repurposed as a safe and effective agent used in combination with other frontline chemotherapy drugs such as cisplatin in HNSCC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 3×
“The combination effects between mebendazole and cisplatin were calculated by using the Chou–Talalay method [27].”
BackgroundMethodInfluentialAntiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor077 · Cited by 201 · cited 3×
“MBZ showed survival benefit in two preclinical models of glioblastoma multiform [8].”
BackgroundMebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152 · cited 1×
“Several studies indicate that MBZ and/or its derivative flubendazole exerted anticancer activities in adrenocortical carcinoma [9], glioblastoma multiform [8], medulloblastoma [10], melanoma [11], leukemia and myeloma [12], non-small cell lung cancer [13, 14], cholangiocarcinoma [15], gastric cancer [16], colon cancer…”
BackgroundRepositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1539-5 · Cited by 133
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice
Martarelli, D., Pompei, P., Baldi, C., & Mazzoni, G. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0538-0 · Cited by 101 · cited 3×
“These findings are consistent with other reports in which MBZ was shown to induce mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells [9, 13].”
BackgroundResult
Cited by
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Self-citationGuerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., et al. (2019) · Cancers · doi:10.3390/cancers11091284 · Cited by 146
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Hu, X., Li, L., Yu, X., Zhang, R., Yan, S., Zeng, Z., Shu, Y., Zhao, C., Wu, X., Lei, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22915 · Cited by 62
Self-citationRepurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., & Leung, H. Y. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0681-5 · Cited by 42
Kralova, V., Hanušová, V., Caltová, K., Špaček, P., Hochmalová, M., Skálová, L., & Rudolf, E. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.026 · Cited by 30
Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells
Park, D., Lee, J.-H., & Yoon, S.-P. (2022) · The Korean Journal of Physiology & Pharmacology · doi:10.4196/kjpp.2022.26.5.377 · Cited by 23
Metadata
- Authors
- Zhang, F., Li, Y., Zhang, H., Huang, E., Gao, L., Luo, W., Wei, Q., Fan, J., Song, D., Liao, J., Zou, Y., Liu, F., Liu, J., Huang, J., Guo, D., Ma, C., Hu, X., Li, L., Qu, X., Chen, L., Yu, X., Zhang, Z., Wu, T., Luu, H. H., Haydon, R. C., Song, J., He, T.-C., & Ji, P.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-01-16
- Volume
- 8
- Issue
- 8
- Pages
- 12968-12982
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2573710850
- Cited by
- 65
- References
- 5
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.